MedDataX Logo

Bifeprunox in the Treatment of Schizophrenia

NCT00193713 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-01-16

No results posted yet for this study

Summary

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Conditions

  • Schizophrenia

Interventions

DRUG

bifeprunox

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Director Solvay · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2006-11-30
Completion
2006-11-30

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00193713 on ClinicalTrials.gov